hackint0sh/New-Dataset huggingface dataset:
To our knowledge, there are no studies evaluating the lung ultrasound findings of asymptomatic vapers. However, there is data to suggest that vaping can lead to pulmonary toxicity in in-vitro and animal models, including increased inflammatory cytokines, hyperreactivity, and oxidative stress. In addition, studies found the risk of bronchitic symptoms is twice as likely in current adolescent vapers, compared to those who have never vaped before. Given the potential pulmonary toxicity of vaping, as well as the increased percentage of adolescent vaping activity in recent years, investigators aim to evaluate baseline lung ultrasound findings in adolescents who vape. Concurrently, investigators will assess if observing their lung ultrasound findings can alter their attitudes and behaviors towards vaping. Prior adult studies have found that showing patients' their atherosclerosis plaque increased the motivation to quit and cessation rates. Additionally, data in pregnant patients found real-time ultrasound feedback of smoking effects on the fetus lead to near abstinence in light smokers. Given the frequent use of point-of-care ultrasound in the emergency department, investigators hope to assess an innovative intervention for cessation. conditions: Vaping studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE maskingDescription: All participants will be randomized on a 1:1 ratio to be able to see and discuss their ultrasound results, or remain blinded to them. whoMasked: PARTICIPANT count: 200 type: ESTIMATED name: Discussion of point-of-care ultrasound lung findings measure: Lung Ultrasound Findings measure: Behavioral Changes sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Medical University of South Carolina city: Charleston state: South Carolina zip: 29412 country: United States name: Kaitlyn Boggs, MD role: CONTACT lat: 32.77657 lon: -79.93092 hasResults: False
nctId: NCT06335316 id: wallenburg sym briefTitle: Effect of Stellate Nerve Block in Dysphagia overallStatus: COMPLETED date: 2022-01-01 date: 2023-05-04 date: 2023-05-28 date: 2024-03-28 date: 2024-03-28 name: Copka Sonpashan class: OTHER_GOV briefSummary: This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in China. Both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. Besides, the observation group additionally underwent the stellate ganglion block (SGB). At admission and after 20-day treatment,Yale Pharyngeal Residue Severity Rating Scale, video fluoroscopic swallowing study (VFSS), Functional Oral Intake Scale, and penetration-aspiration scale (PAS) were used to assess swallowing function. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 122 type: ACTUAL name: Injection name: Lidocaine Hydrochloride name: Comprehensive therapy name: placebo measure: Functional Oral Intake Scale measure: Yale Pharyngeal Residue Severity Rating Scale measure: penetration-aspiration scale measure: The Swallowing Quality of Life Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huimin Hos. city: Pengfu country: Taiwan lat: 24.98333 lon: 121.41667 hasResults: False
nctId: NCT06335303 id: 1462-0004 id: 2023-508395-11-00 type: OTHER domain: CTIS id: U1111-1302-4283 type: OTHER domain: WHO briefTitle: A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) overallStatus: NOT_YET_RECRUITING date: 2024-06-20 date: 2026-04-30 date: 2026-06-30 date: 2024-03-28 date: 2024-03-28 name: Boehringer Ingelheim class: INDUSTRY briefSummary: This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff.
At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects. conditions: Idiopathic Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: BI 1819479 name: Placebo matching BI 1819479 measure: Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year] measure: Absolute change from baseline in FVC at Week 24 [in milliLiter] sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06335290 id: IEO 725 briefTitle: Radiotherapy Treatments for the Treatment of Thoracic District Tumors overallStatus: RECRUITING date: 2018-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-28 name: European Institute of Oncology class: OTHER briefSummary: Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of thoracic radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the thoracic anatomical region. conditions: Thoracic Neoplasms studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 13200 type: ESTIMATED measure: Overall survival measure: Disease free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Barbara Alicja Jereczek role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06335277 id: IEO 0727 briefTitle: Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology overallStatus: RECRUITING date: 2018-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-28 name: European Institute of Oncology class: OTHER briefSummary: Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant. conditions: Leukemia conditions: Leukemia, Chronic conditions: Leukemia, Acute conditions: Lymphoma conditions: Aplastic Anemia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Overall Survival measure: Disease free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Barbara Alicja Jereczek role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06335264 id: 2024-9987 briefTitle: Screening for Heart Failure Using a Multimodal Wearable Device acronym: WEAR-HF overallStatus: RECRUITING date: 2024-01-15 date: 2024-07 date: 2024-12 date: 2024-03-28 date: 2024-03-28 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER name: HOP-Child Technologies Inc briefSummary: The purpose of this study is to find out if there are any patterns in the way people's bodies react to physical activities and their voices when they have heart failure, a disease where the heart cannot function sufficiently. To do this, the investigators will use a smartwatch that can measure multiple signals like the participant's heart rate and movement. Investigators will ask participants with and without heart failure to wear the Watch HOP (from HOP-Child Technologies Inc.) and sensors during physical tasks at their clinic visit at the McGill University Health Centre. Researchers will also record the participants' voices between their visits. The key signals can help find who is at risk for heart failure or develop new ways to monitor and treat it. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 54 type: ESTIMATED name: Watch HOP measure: Presence or absence of heart failure measure: left ventricular ejection fraction (LVEF) measure: Natriuretic peptide (NT-proBNP) level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: McGill University Health Centre status: RECRUITING city: Montreal state: Quebec zip: H4A 3J1 country: Canada name: Abhinav Sharma, MD role: CONTACT phone: 514 934-1934 email: dreamcvlab@muhc.mcgill.ca name: Abhinav Sharma, MD role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06335251 id: IEO 0728 briefTitle: Radiotherapy Treatments for Neoplasms of the Limbs overallStatus: RECRUITING date: 2018-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-28 name: European Institute of Oncology class: OTHER briefSummary: In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included conditions: Bone Neoplasms conditions: Bone Metastases studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED measure: Overall survival measure: Disease free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Barbara Alicja Jereczek role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06335238 id: IEO 0729 briefTitle: Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region overallStatus: RECRUITING date: 2018-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-28 name: European Institute of Oncology class: OTHER briefSummary: Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of abdominal-pelvic region radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the tabdominal-pelvic region. conditions: Abdominal Cancer conditions: Pelvic Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 7700 type: ESTIMATED measure: Overall survival measure: Disease free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Barbara Alicja Jereczek role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06335225 id: 2023-NHLHCRF-YXHZ-ZRMS-06 briefTitle: Establishment of Precise Nutrition Management Scheme for Patients With Prediabetes Based on Nutrigenomics overallStatus: RECRUITING date: 2024-03-13 date: 2025-07-31 date: 2025-07-31 date: 2024-03-28 date: 2024-03-28 name: China-Japan Friendship Hospital class: OTHER briefSummary: With the aging of population and the change of lifestyle, the prevalence of prediabetes is increasing year by year. Nutritional factors are one of the important environmental factors in the occurrence and development of abnormal glucose metabolism. The medical nutritional treatment of diabetes is recommended as the cornerstone of diabetes treatment by various guidelines. With the development of nutrigenomics, it has been found that genes related to the absorption, metabolism, distribution and excretion of various nutrients are related to diabetes. This study intends to conduct precision nutrition intervention for prediabetic patients based on nutritional genes, and evaluate the effectiveness and safety of these nutritional interventions. conditions: Prediabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Precise nutritional intervention name: Conventional nutritional intervention measure: HbA1c measure: Concentration of fasting plasma glucose measure: Concentration of 2-hour plasma glucose measure: Concentration of fasting insulin measure: Concentration of fasting C peptide measure: Concentration of TC, TG, LDL-C, and HDL-C measure: Concentration of ALT, AST, TBIL measure: Concentration of creatinine measure: BMI measure: Waist hip ratio sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China-Japan Friendship Hospital status: RECRUITING city: Beijing country: China name: Xiao Ma, MD role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06335212 id: IRBNET ID 1448963 briefTitle: Peripheral Defocus Profile of Multifocal Minus Contact Lenses overallStatus: COMPLETED date: 2019-06-01 date: 2019-08-01 date: 2019-08-05 date: 2024-03-28 date: 2024-03-28 name: State University of New York College of Optometry class: OTHER briefSummary: Purpose: Numerous studies have proven that emmetropization in young animals including humans is regulated by visual input. It has long been hypothesized that peripheral myopic defocus may act as a stop signal to reduce myopia progression and axial elongation. As such, multifocal soft contact lenses (MFCLs) have been utilized for myopia control in school-aged children, with variable efficacies. One potential explanation is that the actual peripheral myopic defocus an eye experiences during MFCL wear may not be identical to the Add power and not sufficient to reduce myopia progression. Our study investigated and compared the peripheral power profiles of myopic eyes when they were uncorrected and wore single vision contact lenses (SVCLs) and MFCLs of different Add powers.
Methods: Subjects with -1.00 D to -10.00 D of myopia (SE, determined with manifest refraction) were custom fit with both single vision (SV) and MFCLs (+2.00 and +4.00 D Add; provided by Specialeyes) in both eyes. These Specialeyes MFCLs had an aspheric design with a standard total optical zone of 8.0mm. Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia. Data in the right eye was used for analysis. conditions: Myopia conditions: Refractive Errors conditions: Contact Lens studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 19 type: ACTUAL name: Single vision and multifocal contact lenses measure: refractive power sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: State University of New York, College of Optometry city: New York state: New York zip: 10036 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06335199 id: H24109 id: 5P2CHD086844-09 type: NIH link: https://reporter.nih.gov/quickSearch/5P2CHD086844-09 briefTitle: tVNS Responsiveness Testing With Pupil Size overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-03-31 date: 2025-04-30 date: 2024-03-28 date: 2024-04-01 name: Georgia Institute of Technology class: OTHER name: Emory University name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) briefSummary: The goal of this study is to learn about the acute pupil response to transcutaneous vagus nerve stimulation (tVNS) in stroke survivors and healthy adults. The main question it aims to answer is whether pupil size response is greater with bilateral tVNS compared to unilateral tVNS. Participants will receive tVNS and sham at the outer ear unilaterally and bilaterally in resting condition. The pupil size of the participants will be recorded during tVNS. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: Unilateral tVNS stimulation name: Bilateral tVNS stimulation name: Unilateral Sham stimulation name: Bilateral Sham stimulation measure: Pupil size change sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Human Neuromuscular Physiology Lab city: Atlanta state: Georgia zip: 30318 country: United States name: Minoru Shinohara, Ph.D. role: CONTACT phone: 404-894-1030 email: shinohara@gatech.edu lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06335186 id: Soh-Med-24-03-04MS briefTitle: Predictive and Prognostic Significance of Age,Blood Tests,Comorbidities(ABC) Score,Cologne Watch(C-watch)Score and Rockall Score for Risk of Variceal Re-bleeding Among Cirrhotic Patients overallStatus: RECRUITING date: 2024-02-10 date: 2025-03 date: 2025-03 date: 2024-03-28 date: 2024-03-28 name: Sohag University class: OTHER briefSummary: Introduction
Portal hypertension is a common complication of liver cirrhosis and is often underestimated in clinical diagnosis. The incidence of portal hypertension is approximately 20% to 98% in patients with cirrhosis (Wu et al., 2022). It is the major driver in the transition from the compensated to the 'decompensated' stage of cirrhosis, defined by the presence of clinical complications, including ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy (Berzigotti., 2017).
Patients with cirrhosis, although much progress has been made in diagnosis and treatment using vasoactive drugs, preventive antibiotics, early endoscopy and interventional radiology, the 6-week mortality rate remains high, ranging from 10 to 20%, mainly due to failure to control bleeding in the first days. Therefore, the prognostic method of patients with acute variceal bleeding is to determine the risk of rebleeding and resistance to standard treatment (accounting for 20-30%) and mortality rate in order to be able to adopt more aggressive treatment measures. The prognosis is very important but also difficult, not only because of the bleeding status but also depending on the severity of the underlying cirrhosis (Huy et al., 2023).
Many risk assessment score systems, including pre-endoscopy and post-endoscopy evaluations, have been developed to predict outcomes such as the need for hospital-based intervention, endoscopic therapy, and admission to an intensive care unit (ICU), rebleeding, and mortality. Some studies showed that these scoring systems distinguish low-risk patients who can potentially be managed as outpatients, allowing more efficient use of resources. Other studies suggested that these score systems distinguish higher-risk patients who might require emergency endoscopy or management in an intensive care unit (Li et al., 2022).
In 1993, the Rockall Scoring system was introduced to predict the mortality after UGIB and was validated for its use to identify the patients at high risk for re-bleed and mortality. Complete Rockall scoring system is based on an initial clinical score at the time of admission which consist of age (score 0-2), presence of shock (0-2), co-morbidities (score 0-3) and post endoscopic diagnosis (score 0-2) with stigmata of recent hemorrhages (score 0-2). Both clinical and post endoscopic scores added together gives a complete Rockall score with maximum score being 11 (Dewan et al., 2018).
In 2020, Laursen S.B. and colleagues conducted a multicenter international study and developed a new prognostic scoring system for UGIB called the ABC score. This scoring system is based on three criteria: age, blood test results, and comorbidities. The score ranges from 0 to 18 points, categorizing the risk into low (≤3 points), moderate (4-7 points), and high (≥8 points) levels. The 30-day mortality rates for high-risk UGIB patients in these three risk groups were 1%, 7%, and 25%, respectively ( Ky et al., 2023)
The new Cologne Watch (C-Watch) score was designed as a pre-endoscopic score for acute variceal and non-variceal UGIB and incorporates laboratory values only (c-reactive protein, white blood cell count, alanine-aminotransferase, thrombocytes, creatinine, and hemoglobin) with a minimum point value of 0 and a maximum point value of 8. Within the validation set, it predicted a composite endpoint consisting of recurrent bleeding, need for intervention (interventional radiology, surgery), or death within 30 days with an area under the receiver-operating characteristics curve (AUROC) of 0. About 38.7% of patients were within the high-risk group, i.e., ≥2 points, reached the composite endpoint, whereas no patient classified as low risk (≤1 point) (Allo et al., 2022). conditions: Upper Gastrointestinal Variceal Bleeding in Cirrhotic Patients studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: upper endoscopy measure: ABC score. measure: Rockall score sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university Hospital status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06335160 id: Mebendazole Ulcerative Colitis briefTitle: Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-05 date: 2024-03-28 date: 2024-03-28 name: Tanta University class: OTHER briefSummary: To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: Mebendazole measure: change in disease activity measure: change in Partial Mayo Scoring Index (PMSI) assessment for Ulcerative Colitis Activity measure: Change in Hemoglobin Concentration measure: Change in Erythrocyte sedimentation rate (ESR) measure: Change in Serum albumin measure: Change in Serum Interleukin -6 (IL-6) measure: Change in Serum Nitric oxide (NO) measure: Change in Serum Intra cellular adhesion molecule 1 (ICAM-1) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06335147 id: HLX10IIT114 briefTitle: PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-01-31 date: 2026-01-31 date: 2024-03-28 date: 2024-03-28 name: Henan Cancer Hospital class: OTHER_GOV briefSummary: Evaluate the efficacy and safety of PD1 monoclonal antibody combined with mFOLFOX6 neoadjuvant therapy for advanced resectable metastatic colon cancer with enriched pro-inflammatory pan macrophage subpopulations conditions: Metastatic Colon Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 23 type: ESTIMATED name: Serplulimab, mFOLFOX6 measure: pathologic complete response（pCR） measure: Objective response rate (ORR) measure: 2-year overall survival rate measure: Incidence of Treatment-Emergent Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False